Related Experiment Video
Updated: Mar 22, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
North American Thrombosis Forum, AF Action Initiative Consensus Document
Christian T Ruff1, Jack E Ansell2, Richard C Becker3
1Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass.
This consensus document simplifies stroke and bleeding risk assessment for atrial fibrillation patients. It aids clinicians in choosing and managing anticoagulation, improving care for those at risk.
Area of Science:
- Cardiology
- Thrombosis Management
- Clinical Practice Guidelines
Background:
- Atrial fibrillation (AF) necessitates careful stroke and bleeding risk assessment.
- Clinicians face challenges integrating extensive data on risk prediction and anticoagulation.
- Existing guidelines and trial data require synthesis for practical application.
Framework:
- Presents a consensus document from the North American Thrombosis Forum Atrial Fibrillation Action Initiative.
- Focuses on practical risk assessment tools and anticoagulation strategies for AF patients.
- Provides clear recommendations for managing anticoagulation in clinical practice.
Implementation:
- Aims to bridge the gap between complex data and clinical decision-making.
- Facilitates the uptake of updated risk prediction tools.
- Supports the adoption of novel oral anticoagulants (NOACs).
Implications:
- Enhances the ability of healthcare providers to manage AF-related risks effectively.
- Promotes evidence-based anticoagulation management for improved patient outcomes.
- Serves as an educational resource for all clinicians involved in AF patient care.
More Related Videos
Related Concept Videos
Atherosclerosis III: Management
Venous Thrombosis III: Interprofessional Care
Acute Coronary Syndrome III: Diagnostic Studies
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Aneurysm III: Interprofessional Care
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

